Development PipelineLadiratuzumab vedotin

an investigational antibody–drug conjugate directed to LIV-1

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNLVA-002/KEYNOTE-721: First-line metastatic triple-negative breast cancer (LV + pembrolizumab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGNLVA-005: Locally advanced or metastatic solid tumors

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGNLVA-001: Metastatic breast cancer

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of ladiratuzumab vedotin and ongoing clinical trials

Detailed information about ladiratuzumab vedotin clinical trials